API Sulfadimidine Sodium Raw Materials Powder

CAS:1981-58-4

MF:C12H15N4NaO2S

MW:302.33

EINECS:217-840-0

Specification​: 99% min Sulfadimidine Sodium Powder

Sample: Sulfadimidine Sodium Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Sulfadimidine Sodium Powder Usage and Synthesis.

Sulfadimethoxine sodium, the name of a Western medicine. Common dosage forms include injections. It is an antibacterial drug. Used for a variety of infections caused by sensitive bacteria, such as acute simple lower urinary tract infections, acute otitis media and soft tissue skin infections.

Modes of action of Sulfadimidine Sodium.

Sodium sulfadimethoxine belongs to sulfonamides, which is structurally similar to p-aminobenzoic acid (PABA), and can act competitively with PABA on the enzyme of dibasic acid synthase in the body of bacteria, thus preventing the process of synthesising the folic acid required by bacteria as raw material of PABA, and decreasing the amount of metabolically active tetrahydrofolate, which is the bacterial synthesis of purine, thymine nucleoside and deoxyribonucleic acid (DNA). essential for bacterial synthesis of purines, thymine nucleosides and deoxyribonucleic acid (DNA), thus inhibiting bacterial growth and reproduction.

The action of sulphonamides is antagonised by PABA and its derivatives (procaine, bupivacaine), as well as by the presence of pus and the breakdown products of the tissues, which provide essential substances for bacterial growth.

Pharmacological Effects of Sulfadimidine Sodium.

Sulfamethazine sodium is a sulfonamide antimicrobial drug, the antibacterial spectrum is similar to that of sulfadiazine, and it has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella spp., Salmonella spp., Shigella spp. and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae. However, in recent years, the resistance of bacteria to this product has increased, especially Streptococcus, Neisseria and Enterobacteriaceae. The antibacterial mechanism of this product is structurally similar to p-aminobenzoic acid (PABA), can compete with PABA in the bacterial body of dihydrofolate synthase, thus preventing PABA as a raw material for the synthesis of bacterial folic acid needed to reduce the amount of metabolically active tetrahydrofolate, which is the bacterial synthesis of purine, thymine nucleoside and deoxyribonucleic acid (DNA) of the necessary substances, thus inhibits bacterial growth and reproduction.

Drug interactions of Sulfadimidine Sodium.

1、Combining with urine alkalinising drugs can enhance the solubility of the product in alkaline urine and increase excretion.

2, can not be used in combination with p-aminobenzoic acid (PABA), PABA can be replaced by the bacterial uptake of this product, the two antagonistic to each other.

3, the following drugs and this product with the use of this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, so that the drug action time is prolonged or toxicity, therefore, when these drugs and sulfonamides at the same time, or in the application of this product after the use of the dose needs to be adjusted. Such drugs include oral anticoagulants, oral hypoglycaemic agents, methotrexate, phenytoin sodium and sodium thiopental.

The adverse effects of these drugs on the haematopoietic system may be enhanced when combined with myelosuppressive drugs. If there are indications for the co-administration of these two drugs, close observation should be made for possible toxic reactions.

5, and contraceptive drugs (estrogen class) for a long time may lead to reduce the reliability of contraception, and increase the chance of bleeding outside the menstrual period.

6, and thrombolytic drugs, may increase its potential toxic effects.

7, and hepatotoxic drugs, may cause an increase in the incidence of hepatotoxicity. Liver function should be monitored in such patients, especially those who have been using the drug for a long time and have a history of liver disease in the past.

8, with light-sensitive drugs, may occur light-sensitive additive effect.

The need for vitamin K is increased in patients treated with this product.

10, should not be used in combination with urotropin, because urotropin can be decomposed in acidic urine to produce formaldehyde, the latter can be formed with the product insoluble precipitates, so that the risk of crystalluria increased.

11, this product can replace the plasma protein binding site of POTASONE, when the two are used together can enhance the role of POTASONE.